Werewolf Therapeutics, Inc., a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies. Its lead product candidates are WTX-124, a conditionally activated Interleukin-2 INDUKINE molecule for the treatment of advanced solid tumors; and WTX-330, a conditionally activated Interleukin-12 INDUKINE molecule for the treatment of relapsed or refractory advanced or metastatic solid tumors or lymphoma. The company is also developing WTX-613, a conditionally activated interferon alpha INDUKINE molecule for the treatment of solid tumors and hematologic malignancies. Werewolf Therapeutics, Inc. was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.

Werewolf Therapeutics, Inc.

We are an immuno-oncology company advancing a pipeline of next generation, transformative cancer treatments.

DC Investment Partners

HBM Healthcare Investments AG

Adage Capital Management

RA Capital Management

Longwood Fund

MPM Capital

Soleus Capital

Sphera Global Healthcare Fund

Taiho Ventures

UPMC Enterprises

Werewolf Therapeutics

We are excited to share preliminary monotherapy data from our WTX-124 Phase 1/1b clinical trial at Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting. https://bit.ly/45SOV8Y #ImmunoOncology #Cytokines #SITC2023 #HOWL

Excited to be at SITC in San Diego to present 6 posters sharing Wereowlf’s exciting advancement and data!

We’re #hiring a new Accountant in Watertown, Massachusetts. Apply today or share this post with your network.

Werewolf will be @ SITC and would welcome discussions with investors and partners. Reach out to me! See you in San Diego.

We are looking forward to the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting. Be sure to visit our six poster presentations, including interim first-in-human clinical data from our WTX-124 Phase 1/1b study. Learn More: https://lnkd.in/gjjR58w3
#ImmunoOncology #Cytokines #SITC2023 $HOWL

On Sunday 9/24 we are honored to recognize #WorldCancerResearchDay and raise awareness for #cancerresearch. At Werewolf we remain committed to transforming cancer treatment through innovation. Learn more here https://werewolftx.com/

	Dec '19	Dec '20	Dec '21	Dec '22	Dec '23
net income	-10.25M -	-15.04M 46.76%	-49.98M 232.33%	-53.81M 7.66%	-37.37M 30.56%
depreciation and amortization	25K -	150K 500%	216K 44%	1.10M 411.11%	1.76M 59.78%
deferred income tax	-117K -	-7.30M 6,140.17%			4.33M -
stock based compensation	559K -	632K 13.06%	4.09M 547.94%	7.40M 80.71%	8.01M 8.22%
change in working capital	-711K -	2.31M 424.61%	2.28M 1.34%	2.54M 11.51%	-5.89M 332.14%
accounts receivables				-6.93M -	5.58M 180.51%
inventory				6.93M -
accounts payables	116K -	388K 234.48%	1.01M 159.54%	-883K 187.69%	-4.33M 390.94%
other working capital	-827K -	1.92M 332.16%	1.27M 33.85%	3.42M 169.45%	-7.14M 308.56%
other non cash items	950K -	627K 34%	519K 17.22%	2.17M 318.30%	-3.46M 259.24%
net cash provided by operating activities	-9.54M -	-18.62M 95.18%	-42.88M 130.22%	-40.60M 5.32%	-32.61M 19.67%
investments in property plant and equipment	-266K -	-560K 110.53%	-498K 11.07%	-3.61M 625.10%	-769K 78.70%
acquisitions net
purchases of investments
sales maturities of investments
other investing activites
net cash used for investing activites	-266K -	-560K 110.53%	-498K 11.07%	-3.61M 625.10%	-769K 78.70%
debt repayment
common stock issued	2K -	94.01M 4,700,500%	111.60M 18.71%	16.19M 85.49%	58.43M 260.87%
common stock repurchased
dividends paid
other financing activites	21.91M -	-155K 100.71%	-2.17M 1,301.94%	-285K 86.88%
net cash used provided by financing activities	21.91M -	93.86M 328.39%	109.43M 16.59%	15.91M 85.46%	58.43M 267.34%
effect of forex changes on cash					-20.02M -
net change in cash	12.10M -	74.67M 517.08%	66.05M 11.54%	-28.30M 142.85%	5.03M 117.77%
cash at beginning of period	6.00M -	18.10M 201.58%	92.78M 412.47%	158.83M 71.20%	129.31M 18.58%
cash at end of period	18.10M -	92.78M 412.47%	158.83M 71.20%	130.53M 17.82%	134.34M 2.92%
operating cash flow	-9.54M -	-18.62M 95.18%	-42.88M 130.22%	-40.60M 5.32%	-32.61M 19.67%
capital expenditure	-266K -	-560K 110.53%	-498K 11.07%	-3.61M 625.10%	-769K 78.70%
free cash flow	-9.81M -	-19.18M 95.60%	-43.37M 126.09%	-44.21M 1.92%	-33.38M 24.49%

NASDAQ:HOWL

Werewolf Therapeutics, Inc.

Last Close

2.03

25/09 14:38

Market Cap

95.60M

Beta: 0.21

Volume Today

47.32K

Avg: 55.98K

PE Ratio

−6.10

PFCF: −5.35

Preview